Global Bevacizumab Generics Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Bevacizumab generics refer to versions of the medication that are bioequivalent to the original brand-name drug,Avastin.Bevacizumab is a medication used in the treatment of various cancers and certain eye diseases,which works by inhibiting vascular endothelial growth factor(VEGF),a protein that promotes the growth of new blood vessels.
The global Bevacizumab Generics market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Bevacizumab Generics Industry Forecast” looks at past sales and reviews total world Bevacizumab Generics sales in 2023, providing a comprehensive analysis by region and market sector of projected Bevacizumab Generics sales for 2024 through 2030. With Bevacizumab Generics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bevacizumab Generics industry.
This Insight Report provides a comprehensive analysis of the global Bevacizumab Generics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bevacizumab Generics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bevacizumab Generics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bevacizumab Generics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bevacizumab Generics.
United States market for Bevacizumab Generics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Bevacizumab Generics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Bevacizumab Generics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Bevacizumab Generics players cover Amneal Pharmaceuticals, Amgen, Celltrion Healthcare, Pfizer, Qilu Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Bevacizumab Generics market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Bevacizumab Generics market?
What factors are driving Bevacizumab Generics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bevacizumab Generics market opportunities vary by end market size?
How does Bevacizumab Generics break out by Type, by Application?
Bevacizumab generics refer to versions of the medication that are bioequivalent to the original brand-name drug,Avastin.Bevacizumab is a medication used in the treatment of various cancers and certain eye diseases,which works by inhibiting vascular endothelial growth factor(VEGF),a protein that promotes the growth of new blood vessels.
The global Bevacizumab Generics market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Bevacizumab Generics Industry Forecast” looks at past sales and reviews total world Bevacizumab Generics sales in 2023, providing a comprehensive analysis by region and market sector of projected Bevacizumab Generics sales for 2024 through 2030. With Bevacizumab Generics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bevacizumab Generics industry.
This Insight Report provides a comprehensive analysis of the global Bevacizumab Generics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bevacizumab Generics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bevacizumab Generics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bevacizumab Generics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bevacizumab Generics.
United States market for Bevacizumab Generics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Bevacizumab Generics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Bevacizumab Generics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Bevacizumab Generics players cover Amneal Pharmaceuticals, Amgen, Celltrion Healthcare, Pfizer, Qilu Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Bevacizumab Generics market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 100mg per Vial
- 400mg per Vial
- Hospital and Clinic
- Retail Pharmacies
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amneal Pharmaceuticals
- Amgen
- Celltrion Healthcare
- Pfizer
- Qilu Pharma
- Chia Tai Tianqing
- Jiangsu Hengrui Pharmaceuticals
- Innovent
- Bio-Thera Solutions
- SinoCellTech
- Shanghai Henlius Biotech
- Zhejiang Beta Pharma
What is the 10-year outlook for the global Bevacizumab Generics market?
What factors are driving Bevacizumab Generics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bevacizumab Generics market opportunities vary by end market size?
How does Bevacizumab Generics break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Bevacizumab Generics Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Bevacizumab Generics by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Bevacizumab Generics by Country/Region, 2019, 2023 & 2030
2.2 Bevacizumab Generics Segment by Type
2.2.1 100mg per Vial
2.2.2 400mg per Vial
2.3 Bevacizumab Generics Sales by Type
2.3.1 Global Bevacizumab Generics Sales Market Share by Type (2019-2024)
2.3.2 Global Bevacizumab Generics Revenue and Market Share by Type (2019-2024)
2.3.3 Global Bevacizumab Generics Sale Price by Type (2019-2024)
2.4 Bevacizumab Generics Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Bevacizumab Generics Sales by Application
2.5.1 Global Bevacizumab Generics Sale Market Share by Application (2019-2024)
2.5.2 Global Bevacizumab Generics Revenue and Market Share by Application (2019-2024)
2.5.3 Global Bevacizumab Generics Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Bevacizumab Generics Breakdown Data by Company
3.1.1 Global Bevacizumab Generics Annual Sales by Company (2019-2024)
3.1.2 Global Bevacizumab Generics Sales Market Share by Company (2019-2024)
3.2 Global Bevacizumab Generics Annual Revenue by Company (2019-2024)
3.2.1 Global Bevacizumab Generics Revenue by Company (2019-2024)
3.2.2 Global Bevacizumab Generics Revenue Market Share by Company (2019-2024)
3.3 Global Bevacizumab Generics Sale Price by Company
3.4 Key Manufacturers Bevacizumab Generics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Bevacizumab Generics Product Location Distribution
3.4.2 Players Bevacizumab Generics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BEVACIZUMAB GENERICS BY GEOGRAPHIC REGION
4.1 World Historic Bevacizumab Generics Market Size by Geographic Region (2019-2024)
4.1.1 Global Bevacizumab Generics Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Bevacizumab Generics Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Bevacizumab Generics Market Size by Country/Region (2019-2024)
4.2.1 Global Bevacizumab Generics Annual Sales by Country/Region (2019-2024)
4.2.2 Global Bevacizumab Generics Annual Revenue by Country/Region (2019-2024)
4.3 Americas Bevacizumab Generics Sales Growth
4.4 APAC Bevacizumab Generics Sales Growth
4.5 Europe Bevacizumab Generics Sales Growth
4.6 Middle East & Africa Bevacizumab Generics Sales Growth
5 AMERICAS
5.1 Americas Bevacizumab Generics Sales by Country
5.1.1 Americas Bevacizumab Generics Sales by Country (2019-2024)
5.1.2 Americas Bevacizumab Generics Revenue by Country (2019-2024)
5.2 Americas Bevacizumab Generics Sales by Type (2019-2024)
5.3 Americas Bevacizumab Generics Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Bevacizumab Generics Sales by Region
6.1.1 APAC Bevacizumab Generics Sales by Region (2019-2024)
6.1.2 APAC Bevacizumab Generics Revenue by Region (2019-2024)
6.2 APAC Bevacizumab Generics Sales by Type (2019-2024)
6.3 APAC Bevacizumab Generics Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Bevacizumab Generics by Country
7.1.1 Europe Bevacizumab Generics Sales by Country (2019-2024)
7.1.2 Europe Bevacizumab Generics Revenue by Country (2019-2024)
7.2 Europe Bevacizumab Generics Sales by Type (2019-2024)
7.3 Europe Bevacizumab Generics Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Bevacizumab Generics by Country
8.1.1 Middle East & Africa Bevacizumab Generics Sales by Country (2019-2024)
8.1.2 Middle East & Africa Bevacizumab Generics Revenue by Country (2019-2024)
8.2 Middle East & Africa Bevacizumab Generics Sales by Type (2019-2024)
8.3 Middle East & Africa Bevacizumab Generics Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Bevacizumab Generics
10.3 Manufacturing Process Analysis of Bevacizumab Generics
10.4 Industry Chain Structure of Bevacizumab Generics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Bevacizumab Generics Distributors
11.3 Bevacizumab Generics Customer
12 WORLD FORECAST REVIEW FOR BEVACIZUMAB GENERICS BY GEOGRAPHIC REGION
12.1 Global Bevacizumab Generics Market Size Forecast by Region
12.1.1 Global Bevacizumab Generics Forecast by Region (2025-2030)
12.1.2 Global Bevacizumab Generics Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Bevacizumab Generics Forecast by Type (2025-2030)
12.7 Global Bevacizumab Generics Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Amneal Pharmaceuticals
13.1.1 Amneal Pharmaceuticals Company Information
13.1.2 Amneal Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
13.1.3 Amneal Pharmaceuticals Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Amneal Pharmaceuticals Main Business Overview
13.1.5 Amneal Pharmaceuticals Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Bevacizumab Generics Product Portfolios and Specifications
13.2.3 Amgen Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Celltrion Healthcare
13.3.1 Celltrion Healthcare Company Information
13.3.2 Celltrion Healthcare Bevacizumab Generics Product Portfolios and Specifications
13.3.3 Celltrion Healthcare Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Celltrion Healthcare Main Business Overview
13.3.5 Celltrion Healthcare Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Bevacizumab Generics Product Portfolios and Specifications
13.4.3 Pfizer Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Qilu Pharma
13.5.1 Qilu Pharma Company Information
13.5.2 Qilu Pharma Bevacizumab Generics Product Portfolios and Specifications
13.5.3 Qilu Pharma Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Qilu Pharma Main Business Overview
13.5.5 Qilu Pharma Latest Developments
13.6 Chia Tai Tianqing
13.6.1 Chia Tai Tianqing Company Information
13.6.2 Chia Tai Tianqing Bevacizumab Generics Product Portfolios and Specifications
13.6.3 Chia Tai Tianqing Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Chia Tai Tianqing Main Business Overview
13.6.5 Chia Tai Tianqing Latest Developments
13.7 Jiangsu Hengrui Pharmaceuticals
13.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.7.2 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
13.7.3 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.7.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.8 Innovent
13.8.1 Innovent Company Information
13.8.2 Innovent Bevacizumab Generics Product Portfolios and Specifications
13.8.3 Innovent Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Innovent Main Business Overview
13.8.5 Innovent Latest Developments
13.9 Bio-Thera Solutions
13.9.1 Bio-Thera Solutions Company Information
13.9.2 Bio-Thera Solutions Bevacizumab Generics Product Portfolios and Specifications
13.9.3 Bio-Thera Solutions Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Bio-Thera Solutions Main Business Overview
13.9.5 Bio-Thera Solutions Latest Developments
13.10 SinoCellTech
13.10.1 SinoCellTech Company Information
13.10.2 SinoCellTech Bevacizumab Generics Product Portfolios and Specifications
13.10.3 SinoCellTech Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 SinoCellTech Main Business Overview
13.10.5 SinoCellTech Latest Developments
13.11 Shanghai Henlius Biotech
13.11.1 Shanghai Henlius Biotech Company Information
13.11.2 Shanghai Henlius Biotech Bevacizumab Generics Product Portfolios and Specifications
13.11.3 Shanghai Henlius Biotech Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Shanghai Henlius Biotech Main Business Overview
13.11.5 Shanghai Henlius Biotech Latest Developments
13.12 Zhejiang Beta Pharma
13.12.1 Zhejiang Beta Pharma Company Information
13.12.2 Zhejiang Beta Pharma Bevacizumab Generics Product Portfolios and Specifications
13.12.3 Zhejiang Beta Pharma Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Zhejiang Beta Pharma Main Business Overview
13.12.5 Zhejiang Beta Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Bevacizumab Generics Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Bevacizumab Generics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of 100mg per Vial
Table 4. Major Players of 400mg per Vial
Table 5. Global Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 6. Global Bevacizumab Generics Sales Market Share byType (2019-2024)
Table 7. Global Bevacizumab Generics Revenue byType (2019-2024) & ($ million)
Table 8. Global Bevacizumab Generics Revenue Market Share byType (2019-2024)
Table 9. Global Bevacizumab Generics Sale Price byType (2019-2024) & (US$/Dose)
Table 10. Global Bevacizumab Generics Sale by Application (2019-2024) & (K Dose)
Table 11. Global Bevacizumab Generics Sale Market Share by Application (2019-2024)
Table 12. Global Bevacizumab Generics Revenue by Application (2019-2024) & ($ million)
Table 13. Global Bevacizumab Generics Revenue Market Share by Application (2019-2024)
Table 14. Global Bevacizumab Generics Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Bevacizumab Generics Sales by Company (2019-2024) & (K Dose)
Table 16. Global Bevacizumab Generics Sales Market Share by Company (2019-2024)
Table 17. Global Bevacizumab Generics Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Bevacizumab Generics Revenue Market Share by Company (2019-2024)
Table 19. Global Bevacizumab Generics Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Bevacizumab Generics Producing Area Distribution and Sales Area
Table 21. Players Bevacizumab Generics Products Offered
Table 22. Bevacizumab Generics Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Bevacizumab Generics Sales by Geographic Region (2019-2024) & (K Dose)
Table 26. Global Bevacizumab Generics Sales Market Share Geographic Region (2019-2024)
Table 27. Global Bevacizumab Generics Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Bevacizumab Generics Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Bevacizumab Generics Sales by Country/Region (2019-2024) & (K Dose)
Table 30. Global Bevacizumab Generics Sales Market Share by Country/Region (2019-2024)
Table 31. Global Bevacizumab Generics Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Bevacizumab Generics Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
Table 34. Americas Bevacizumab Generics Sales Market Share by Country (2019-2024)
Table 35. Americas Bevacizumab Generics Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 37. Americas Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
Table 38. APAC Bevacizumab Generics Sales by Region (2019-2024) & (K Dose)
Table 39. APAC Bevacizumab Generics Sales Market Share by Region (2019-2024)
Table 40. APAC Bevacizumab Generics Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 42. APAC Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
Table 43. Europe Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
Table 44. Europe Bevacizumab Generics Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 46. Europe Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
Table 47. Middle East & Africa Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
Table 48. Middle East & Africa Bevacizumab Generics Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 50. Middle East & Africa Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
Table 51. Key Market Drivers & Growth Opportunities of Bevacizumab Generics
Table 52. Key Market Challenges & Risks of Bevacizumab Generics
Table 53. Key IndustryTrends of Bevacizumab Generics
Table 54. Bevacizumab Generics Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Bevacizumab Generics Distributors List
Table 57. Bevacizumab Generics Customer List
Table 58. Global Bevacizumab Generics SalesForecast by Region (2025-2030) & (K Dose)
Table 59. Global Bevacizumab Generics RevenueForecast by Region (2025-2030) & ($ millions)
Table 60. Americas Bevacizumab Generics SalesForecast by Country (2025-2030) & (K Dose)
Table 61. Americas Bevacizumab Generics Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 62. APAC Bevacizumab Generics SalesForecast by Region (2025-2030) & (K Dose)
Table 63. APAC Bevacizumab Generics Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Europe Bevacizumab Generics SalesForecast by Country (2025-2030) & (K Dose)
Table 65. Europe Bevacizumab Generics RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Bevacizumab Generics SalesForecast by Country (2025-2030) & (K Dose)
Table 67. Middle East & Africa Bevacizumab Generics RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Global Bevacizumab Generics SalesForecast byType (2025-2030) & (K Dose)
Table 69. Global Bevacizumab Generics RevenueForecast byType (2025-2030) & ($ millions)
Table 70. Global Bevacizumab Generics SalesForecast by Application (2025-2030) & (K Dose)
Table 71. Global Bevacizumab Generics RevenueForecast by Application (2025-2030) & ($ millions)
Table 72. Amneal Pharmaceuticals Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 73. Amneal Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
Table 74. Amneal Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Amneal Pharmaceuticals Main Business
Table 76. Amneal Pharmaceuticals Latest Developments
Table 77. Amgen Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 78. Amgen Bevacizumab Generics Product Portfolios and Specifications
Table 79. Amgen Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80. Amgen Main Business
Table 81. Amgen Latest Developments
Table 82. Celltrion Healthcare Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 83. Celltrion Healthcare Bevacizumab Generics Product Portfolios and Specifications
Table 84. Celltrion Healthcare Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. Celltrion Healthcare Main Business
Table 86. Celltrion Healthcare Latest Developments
Table 87. Pfizer Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 88. Pfizer Bevacizumab Generics Product Portfolios and Specifications
Table 89. Pfizer Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. Pfizer Main Business
Table 91. Pfizer Latest Developments
Table 92. Qilu Pharma Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 93. Qilu Pharma Bevacizumab Generics Product Portfolios and Specifications
Table 94. Qilu Pharma Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 95. Qilu Pharma Main Business
Table 96. Qilu Pharma Latest Developments
Table 97. ChiaTaiTianqing Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 98. ChiaTaiTianqing Bevacizumab Generics Product Portfolios and Specifications
Table 99. ChiaTaiTianqing Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 100. ChiaTaiTianqing Main Business
Table 101. ChiaTaiTianqing Latest Developments
Table 102. Jiangsu Hengrui Pharmaceuticals Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 103. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
Table 104. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 105. Jiangsu Hengrui Pharmaceuticals Main Business
Table 106. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 107. Innovent Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 108. Innovent Bevacizumab Generics Product Portfolios and Specifications
Table 109. Innovent Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 110. Innovent Main Business
Table 111. Innovent Latest Developments
Table 112. Bio-Thera Solutions Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 113. Bio-Thera Solutions Bevacizumab Generics Product Portfolios and Specifications
Table 114. Bio-Thera Solutions Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 115. Bio-Thera Solutions Main Business
Table 116. Bio-Thera Solutions Latest Developments
Table 117. SinoCellTech Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 118. SinoCellTech Bevacizumab Generics Product Portfolios and Specifications
Table 119. SinoCellTech Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 120. SinoCellTech Main Business
Table 121. SinoCellTech Latest Developments
Table 122. Shanghai Henlius Biotech Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 123. Shanghai Henlius Biotech Bevacizumab Generics Product Portfolios and Specifications
Table 124. Shanghai Henlius Biotech Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 125. Shanghai Henlius Biotech Main Business
Table 126. Shanghai Henlius Biotech Latest Developments
Table 127. Zhejiang Beta Pharma Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 128. Zhejiang Beta Pharma Bevacizumab Generics Product Portfolios and Specifications
Table 129. Zhejiang Beta Pharma Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 130. Zhejiang Beta Pharma Main Business
Table 131. Zhejiang Beta Pharma Latest Developments
LIST OFFIGURES
Figure 1. Picture of Bevacizumab Generics
Figure 2. Bevacizumab Generics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Bevacizumab Generics Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Bevacizumab Generics Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Bevacizumab Generics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Bevacizumab Generics Sales Market Share by Country/Region (2023)
Figure 10. Bevacizumab Generics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of 100mg per Vial
Figure 12. Product Picture of 400mg per Vial
Figure 13. Global Bevacizumab Generics Sales Market Share byType in 2023
Figure 14. Global Bevacizumab Generics Revenue Market Share byType (2019-2024)
Figure 15. Bevacizumab Generics Consumed in Hospital and Clinic
Figure 16. Global Bevacizumab Generics Market: Hospital and Clinic (2019-2024) & (K Dose)
Figure 17. Bevacizumab Generics Consumed in Retail Pharmacies
Figure 18. Global Bevacizumab Generics Market: Retail Pharmacies (2019-2024) & (K Dose)
Figure 19. Bevacizumab Generics Consumed in Other
Figure 20. Global Bevacizumab Generics Market: Other (2019-2024) & (K Dose)
Figure 21. Global Bevacizumab Generics Sale Market Share by Application (2023)
Figure 22. Global Bevacizumab Generics Revenue Market Share by Application in 2023
Figure 23. Bevacizumab Generics Sales by Company in 2023 (K Dose)
Figure 24. Global Bevacizumab Generics Sales Market Share by Company in 2023
Figure 25. Bevacizumab Generics Revenue by Company in 2023 ($ millions)
Figure 26. Global Bevacizumab Generics Revenue Market Share by Company in 2023
Figure 27. Global Bevacizumab Generics Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Bevacizumab Generics Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Bevacizumab Generics Sales 2019-2024 (K Dose)
Figure 30. Americas Bevacizumab Generics Revenue 2019-2024 ($ millions)
Figure 31. APAC Bevacizumab Generics Sales 2019-2024 (K Dose)
Figure 32. APAC Bevacizumab Generics Revenue 2019-2024 ($ millions)
Figure 33. Europe Bevacizumab Generics Sales 2019-2024 (K Dose)
Figure 34. Europe Bevacizumab Generics Revenue 2019-2024 ($ millions)
Figure 35. Middle East & Africa Bevacizumab Generics Sales 2019-2024 (K Dose)
Figure 36. Middle East & Africa Bevacizumab Generics Revenue 2019-2024 ($ millions)
Figure 37. Americas Bevacizumab Generics Sales Market Share by Country in 2023
Figure 38. Americas Bevacizumab Generics Revenue Market Share by Country (2019-2024)
Figure 39. Americas Bevacizumab Generics Sales Market Share byType (2019-2024)
Figure 40. Americas Bevacizumab Generics Sales Market Share by Application (2019-2024)
Figure 41. United States Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 42. Canada Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 43. Mexico Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 44. Brazil Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 45. APAC Bevacizumab Generics Sales Market Share by Region in 2023
Figure 46. APAC Bevacizumab Generics Revenue Market Share by Region (2019-2024)
Figure 47. APAC Bevacizumab Generics Sales Market Share byType (2019-2024)
Figure 48. APAC Bevacizumab Generics Sales Market Share by Application (2019-2024)
Figure 49. China Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 50. Japan Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 51. South Korea Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 52. Southeast Asia Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 53. India Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 54. Australia Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 55. ChinaTaiwan Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 56. Europe Bevacizumab Generics Sales Market Share by Country in 2023
Figure 57. Europe Bevacizumab Generics Revenue Market Share by Country (2019-2024)
Figure 58. Europe Bevacizumab Generics Sales Market Share byType (2019-2024)
Figure 59. Europe Bevacizumab Generics Sales Market Share by Application (2019-2024)
Figure 60. Germany Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 61.France Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 62. UK Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 63. Italy Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 64. Russia Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 65. Middle East & Africa Bevacizumab Generics Sales Market Share by Country (2019-2024)
Figure 66. Middle East & Africa Bevacizumab Generics Sales Market Share byType (2019-2024)
Figure 67. Middle East & Africa Bevacizumab Generics Sales Market Share by Application (2019-2024)
Figure 68. Egypt Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 69. South Africa Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 70. Israel Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 71.Turkey Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 72. GCC Countries Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Bevacizumab Generics in 2023
Figure 74. Manufacturing Process Analysis of Bevacizumab Generics
Figure 75. Industry Chain Structure of Bevacizumab Generics
Figure 76. Channels of Distribution
Figure 77. Global Bevacizumab Generics Sales MarketForecast by Region (2025-2030)
Figure 78. Global Bevacizumab Generics Revenue Market ShareForecast by Region (2025-2030)
Figure 79. Global Bevacizumab Generics Sales Market ShareForecast byType (2025-2030)
Figure 80. Global Bevacizumab Generics Revenue Market ShareForecast byType (2025-2030)
Figure 81. Global Bevacizumab Generics Sales Market ShareForecast by Application (2025-2030)
Figure 82. Global Bevacizumab Generics Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Bevacizumab Generics Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Bevacizumab Generics by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Bevacizumab Generics by Country/Region, 2019, 2023 & 2030
2.2 Bevacizumab Generics Segment by Type
2.2.1 100mg per Vial
2.2.2 400mg per Vial
2.3 Bevacizumab Generics Sales by Type
2.3.1 Global Bevacizumab Generics Sales Market Share by Type (2019-2024)
2.3.2 Global Bevacizumab Generics Revenue and Market Share by Type (2019-2024)
2.3.3 Global Bevacizumab Generics Sale Price by Type (2019-2024)
2.4 Bevacizumab Generics Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Bevacizumab Generics Sales by Application
2.5.1 Global Bevacizumab Generics Sale Market Share by Application (2019-2024)
2.5.2 Global Bevacizumab Generics Revenue and Market Share by Application (2019-2024)
2.5.3 Global Bevacizumab Generics Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Bevacizumab Generics Breakdown Data by Company
3.1.1 Global Bevacizumab Generics Annual Sales by Company (2019-2024)
3.1.2 Global Bevacizumab Generics Sales Market Share by Company (2019-2024)
3.2 Global Bevacizumab Generics Annual Revenue by Company (2019-2024)
3.2.1 Global Bevacizumab Generics Revenue by Company (2019-2024)
3.2.2 Global Bevacizumab Generics Revenue Market Share by Company (2019-2024)
3.3 Global Bevacizumab Generics Sale Price by Company
3.4 Key Manufacturers Bevacizumab Generics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Bevacizumab Generics Product Location Distribution
3.4.2 Players Bevacizumab Generics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BEVACIZUMAB GENERICS BY GEOGRAPHIC REGION
4.1 World Historic Bevacizumab Generics Market Size by Geographic Region (2019-2024)
4.1.1 Global Bevacizumab Generics Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Bevacizumab Generics Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Bevacizumab Generics Market Size by Country/Region (2019-2024)
4.2.1 Global Bevacizumab Generics Annual Sales by Country/Region (2019-2024)
4.2.2 Global Bevacizumab Generics Annual Revenue by Country/Region (2019-2024)
4.3 Americas Bevacizumab Generics Sales Growth
4.4 APAC Bevacizumab Generics Sales Growth
4.5 Europe Bevacizumab Generics Sales Growth
4.6 Middle East & Africa Bevacizumab Generics Sales Growth
5 AMERICAS
5.1 Americas Bevacizumab Generics Sales by Country
5.1.1 Americas Bevacizumab Generics Sales by Country (2019-2024)
5.1.2 Americas Bevacizumab Generics Revenue by Country (2019-2024)
5.2 Americas Bevacizumab Generics Sales by Type (2019-2024)
5.3 Americas Bevacizumab Generics Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Bevacizumab Generics Sales by Region
6.1.1 APAC Bevacizumab Generics Sales by Region (2019-2024)
6.1.2 APAC Bevacizumab Generics Revenue by Region (2019-2024)
6.2 APAC Bevacizumab Generics Sales by Type (2019-2024)
6.3 APAC Bevacizumab Generics Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Bevacizumab Generics by Country
7.1.1 Europe Bevacizumab Generics Sales by Country (2019-2024)
7.1.2 Europe Bevacizumab Generics Revenue by Country (2019-2024)
7.2 Europe Bevacizumab Generics Sales by Type (2019-2024)
7.3 Europe Bevacizumab Generics Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Bevacizumab Generics by Country
8.1.1 Middle East & Africa Bevacizumab Generics Sales by Country (2019-2024)
8.1.2 Middle East & Africa Bevacizumab Generics Revenue by Country (2019-2024)
8.2 Middle East & Africa Bevacizumab Generics Sales by Type (2019-2024)
8.3 Middle East & Africa Bevacizumab Generics Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Bevacizumab Generics
10.3 Manufacturing Process Analysis of Bevacizumab Generics
10.4 Industry Chain Structure of Bevacizumab Generics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Bevacizumab Generics Distributors
11.3 Bevacizumab Generics Customer
12 WORLD FORECAST REVIEW FOR BEVACIZUMAB GENERICS BY GEOGRAPHIC REGION
12.1 Global Bevacizumab Generics Market Size Forecast by Region
12.1.1 Global Bevacizumab Generics Forecast by Region (2025-2030)
12.1.2 Global Bevacizumab Generics Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Bevacizumab Generics Forecast by Type (2025-2030)
12.7 Global Bevacizumab Generics Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Amneal Pharmaceuticals
13.1.1 Amneal Pharmaceuticals Company Information
13.1.2 Amneal Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
13.1.3 Amneal Pharmaceuticals Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Amneal Pharmaceuticals Main Business Overview
13.1.5 Amneal Pharmaceuticals Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Bevacizumab Generics Product Portfolios and Specifications
13.2.3 Amgen Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Celltrion Healthcare
13.3.1 Celltrion Healthcare Company Information
13.3.2 Celltrion Healthcare Bevacizumab Generics Product Portfolios and Specifications
13.3.3 Celltrion Healthcare Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Celltrion Healthcare Main Business Overview
13.3.5 Celltrion Healthcare Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Bevacizumab Generics Product Portfolios and Specifications
13.4.3 Pfizer Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Qilu Pharma
13.5.1 Qilu Pharma Company Information
13.5.2 Qilu Pharma Bevacizumab Generics Product Portfolios and Specifications
13.5.3 Qilu Pharma Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Qilu Pharma Main Business Overview
13.5.5 Qilu Pharma Latest Developments
13.6 Chia Tai Tianqing
13.6.1 Chia Tai Tianqing Company Information
13.6.2 Chia Tai Tianqing Bevacizumab Generics Product Portfolios and Specifications
13.6.3 Chia Tai Tianqing Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Chia Tai Tianqing Main Business Overview
13.6.5 Chia Tai Tianqing Latest Developments
13.7 Jiangsu Hengrui Pharmaceuticals
13.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.7.2 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
13.7.3 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.7.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.8 Innovent
13.8.1 Innovent Company Information
13.8.2 Innovent Bevacizumab Generics Product Portfolios and Specifications
13.8.3 Innovent Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Innovent Main Business Overview
13.8.5 Innovent Latest Developments
13.9 Bio-Thera Solutions
13.9.1 Bio-Thera Solutions Company Information
13.9.2 Bio-Thera Solutions Bevacizumab Generics Product Portfolios and Specifications
13.9.3 Bio-Thera Solutions Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Bio-Thera Solutions Main Business Overview
13.9.5 Bio-Thera Solutions Latest Developments
13.10 SinoCellTech
13.10.1 SinoCellTech Company Information
13.10.2 SinoCellTech Bevacizumab Generics Product Portfolios and Specifications
13.10.3 SinoCellTech Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 SinoCellTech Main Business Overview
13.10.5 SinoCellTech Latest Developments
13.11 Shanghai Henlius Biotech
13.11.1 Shanghai Henlius Biotech Company Information
13.11.2 Shanghai Henlius Biotech Bevacizumab Generics Product Portfolios and Specifications
13.11.3 Shanghai Henlius Biotech Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Shanghai Henlius Biotech Main Business Overview
13.11.5 Shanghai Henlius Biotech Latest Developments
13.12 Zhejiang Beta Pharma
13.12.1 Zhejiang Beta Pharma Company Information
13.12.2 Zhejiang Beta Pharma Bevacizumab Generics Product Portfolios and Specifications
13.12.3 Zhejiang Beta Pharma Bevacizumab Generics Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Zhejiang Beta Pharma Main Business Overview
13.12.5 Zhejiang Beta Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Bevacizumab Generics Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Bevacizumab Generics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of 100mg per Vial
Table 4. Major Players of 400mg per Vial
Table 5. Global Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 6. Global Bevacizumab Generics Sales Market Share byType (2019-2024)
Table 7. Global Bevacizumab Generics Revenue byType (2019-2024) & ($ million)
Table 8. Global Bevacizumab Generics Revenue Market Share byType (2019-2024)
Table 9. Global Bevacizumab Generics Sale Price byType (2019-2024) & (US$/Dose)
Table 10. Global Bevacizumab Generics Sale by Application (2019-2024) & (K Dose)
Table 11. Global Bevacizumab Generics Sale Market Share by Application (2019-2024)
Table 12. Global Bevacizumab Generics Revenue by Application (2019-2024) & ($ million)
Table 13. Global Bevacizumab Generics Revenue Market Share by Application (2019-2024)
Table 14. Global Bevacizumab Generics Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Bevacizumab Generics Sales by Company (2019-2024) & (K Dose)
Table 16. Global Bevacizumab Generics Sales Market Share by Company (2019-2024)
Table 17. Global Bevacizumab Generics Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Bevacizumab Generics Revenue Market Share by Company (2019-2024)
Table 19. Global Bevacizumab Generics Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Bevacizumab Generics Producing Area Distribution and Sales Area
Table 21. Players Bevacizumab Generics Products Offered
Table 22. Bevacizumab Generics Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Bevacizumab Generics Sales by Geographic Region (2019-2024) & (K Dose)
Table 26. Global Bevacizumab Generics Sales Market Share Geographic Region (2019-2024)
Table 27. Global Bevacizumab Generics Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Bevacizumab Generics Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Bevacizumab Generics Sales by Country/Region (2019-2024) & (K Dose)
Table 30. Global Bevacizumab Generics Sales Market Share by Country/Region (2019-2024)
Table 31. Global Bevacizumab Generics Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Bevacizumab Generics Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
Table 34. Americas Bevacizumab Generics Sales Market Share by Country (2019-2024)
Table 35. Americas Bevacizumab Generics Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 37. Americas Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
Table 38. APAC Bevacizumab Generics Sales by Region (2019-2024) & (K Dose)
Table 39. APAC Bevacizumab Generics Sales Market Share by Region (2019-2024)
Table 40. APAC Bevacizumab Generics Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 42. APAC Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
Table 43. Europe Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
Table 44. Europe Bevacizumab Generics Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 46. Europe Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
Table 47. Middle East & Africa Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
Table 48. Middle East & Africa Bevacizumab Generics Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Bevacizumab Generics Sales byType (2019-2024) & (K Dose)
Table 50. Middle East & Africa Bevacizumab Generics Sales by Application (2019-2024) & (K Dose)
Table 51. Key Market Drivers & Growth Opportunities of Bevacizumab Generics
Table 52. Key Market Challenges & Risks of Bevacizumab Generics
Table 53. Key IndustryTrends of Bevacizumab Generics
Table 54. Bevacizumab Generics Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Bevacizumab Generics Distributors List
Table 57. Bevacizumab Generics Customer List
Table 58. Global Bevacizumab Generics SalesForecast by Region (2025-2030) & (K Dose)
Table 59. Global Bevacizumab Generics RevenueForecast by Region (2025-2030) & ($ millions)
Table 60. Americas Bevacizumab Generics SalesForecast by Country (2025-2030) & (K Dose)
Table 61. Americas Bevacizumab Generics Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 62. APAC Bevacizumab Generics SalesForecast by Region (2025-2030) & (K Dose)
Table 63. APAC Bevacizumab Generics Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Europe Bevacizumab Generics SalesForecast by Country (2025-2030) & (K Dose)
Table 65. Europe Bevacizumab Generics RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Bevacizumab Generics SalesForecast by Country (2025-2030) & (K Dose)
Table 67. Middle East & Africa Bevacizumab Generics RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Global Bevacizumab Generics SalesForecast byType (2025-2030) & (K Dose)
Table 69. Global Bevacizumab Generics RevenueForecast byType (2025-2030) & ($ millions)
Table 70. Global Bevacizumab Generics SalesForecast by Application (2025-2030) & (K Dose)
Table 71. Global Bevacizumab Generics RevenueForecast by Application (2025-2030) & ($ millions)
Table 72. Amneal Pharmaceuticals Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 73. Amneal Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
Table 74. Amneal Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Amneal Pharmaceuticals Main Business
Table 76. Amneal Pharmaceuticals Latest Developments
Table 77. Amgen Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 78. Amgen Bevacizumab Generics Product Portfolios and Specifications
Table 79. Amgen Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80. Amgen Main Business
Table 81. Amgen Latest Developments
Table 82. Celltrion Healthcare Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 83. Celltrion Healthcare Bevacizumab Generics Product Portfolios and Specifications
Table 84. Celltrion Healthcare Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. Celltrion Healthcare Main Business
Table 86. Celltrion Healthcare Latest Developments
Table 87. Pfizer Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 88. Pfizer Bevacizumab Generics Product Portfolios and Specifications
Table 89. Pfizer Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. Pfizer Main Business
Table 91. Pfizer Latest Developments
Table 92. Qilu Pharma Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 93. Qilu Pharma Bevacizumab Generics Product Portfolios and Specifications
Table 94. Qilu Pharma Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 95. Qilu Pharma Main Business
Table 96. Qilu Pharma Latest Developments
Table 97. ChiaTaiTianqing Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 98. ChiaTaiTianqing Bevacizumab Generics Product Portfolios and Specifications
Table 99. ChiaTaiTianqing Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 100. ChiaTaiTianqing Main Business
Table 101. ChiaTaiTianqing Latest Developments
Table 102. Jiangsu Hengrui Pharmaceuticals Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 103. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolios and Specifications
Table 104. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 105. Jiangsu Hengrui Pharmaceuticals Main Business
Table 106. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 107. Innovent Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 108. Innovent Bevacizumab Generics Product Portfolios and Specifications
Table 109. Innovent Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 110. Innovent Main Business
Table 111. Innovent Latest Developments
Table 112. Bio-Thera Solutions Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 113. Bio-Thera Solutions Bevacizumab Generics Product Portfolios and Specifications
Table 114. Bio-Thera Solutions Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 115. Bio-Thera Solutions Main Business
Table 116. Bio-Thera Solutions Latest Developments
Table 117. SinoCellTech Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 118. SinoCellTech Bevacizumab Generics Product Portfolios and Specifications
Table 119. SinoCellTech Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 120. SinoCellTech Main Business
Table 121. SinoCellTech Latest Developments
Table 122. Shanghai Henlius Biotech Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 123. Shanghai Henlius Biotech Bevacizumab Generics Product Portfolios and Specifications
Table 124. Shanghai Henlius Biotech Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 125. Shanghai Henlius Biotech Main Business
Table 126. Shanghai Henlius Biotech Latest Developments
Table 127. Zhejiang Beta Pharma Basic Information, Bevacizumab Generics Manufacturing Base, Sales Area and Its Competitors
Table 128. Zhejiang Beta Pharma Bevacizumab Generics Product Portfolios and Specifications
Table 129. Zhejiang Beta Pharma Bevacizumab Generics Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 130. Zhejiang Beta Pharma Main Business
Table 131. Zhejiang Beta Pharma Latest Developments
LIST OFFIGURES
Figure 1. Picture of Bevacizumab Generics
Figure 2. Bevacizumab Generics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Bevacizumab Generics Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Bevacizumab Generics Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Bevacizumab Generics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Bevacizumab Generics Sales Market Share by Country/Region (2023)
Figure 10. Bevacizumab Generics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of 100mg per Vial
Figure 12. Product Picture of 400mg per Vial
Figure 13. Global Bevacizumab Generics Sales Market Share byType in 2023
Figure 14. Global Bevacizumab Generics Revenue Market Share byType (2019-2024)
Figure 15. Bevacizumab Generics Consumed in Hospital and Clinic
Figure 16. Global Bevacizumab Generics Market: Hospital and Clinic (2019-2024) & (K Dose)
Figure 17. Bevacizumab Generics Consumed in Retail Pharmacies
Figure 18. Global Bevacizumab Generics Market: Retail Pharmacies (2019-2024) & (K Dose)
Figure 19. Bevacizumab Generics Consumed in Other
Figure 20. Global Bevacizumab Generics Market: Other (2019-2024) & (K Dose)
Figure 21. Global Bevacizumab Generics Sale Market Share by Application (2023)
Figure 22. Global Bevacizumab Generics Revenue Market Share by Application in 2023
Figure 23. Bevacizumab Generics Sales by Company in 2023 (K Dose)
Figure 24. Global Bevacizumab Generics Sales Market Share by Company in 2023
Figure 25. Bevacizumab Generics Revenue by Company in 2023 ($ millions)
Figure 26. Global Bevacizumab Generics Revenue Market Share by Company in 2023
Figure 27. Global Bevacizumab Generics Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Bevacizumab Generics Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Bevacizumab Generics Sales 2019-2024 (K Dose)
Figure 30. Americas Bevacizumab Generics Revenue 2019-2024 ($ millions)
Figure 31. APAC Bevacizumab Generics Sales 2019-2024 (K Dose)
Figure 32. APAC Bevacizumab Generics Revenue 2019-2024 ($ millions)
Figure 33. Europe Bevacizumab Generics Sales 2019-2024 (K Dose)
Figure 34. Europe Bevacizumab Generics Revenue 2019-2024 ($ millions)
Figure 35. Middle East & Africa Bevacizumab Generics Sales 2019-2024 (K Dose)
Figure 36. Middle East & Africa Bevacizumab Generics Revenue 2019-2024 ($ millions)
Figure 37. Americas Bevacizumab Generics Sales Market Share by Country in 2023
Figure 38. Americas Bevacizumab Generics Revenue Market Share by Country (2019-2024)
Figure 39. Americas Bevacizumab Generics Sales Market Share byType (2019-2024)
Figure 40. Americas Bevacizumab Generics Sales Market Share by Application (2019-2024)
Figure 41. United States Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 42. Canada Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 43. Mexico Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 44. Brazil Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 45. APAC Bevacizumab Generics Sales Market Share by Region in 2023
Figure 46. APAC Bevacizumab Generics Revenue Market Share by Region (2019-2024)
Figure 47. APAC Bevacizumab Generics Sales Market Share byType (2019-2024)
Figure 48. APAC Bevacizumab Generics Sales Market Share by Application (2019-2024)
Figure 49. China Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 50. Japan Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 51. South Korea Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 52. Southeast Asia Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 53. India Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 54. Australia Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 55. ChinaTaiwan Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 56. Europe Bevacizumab Generics Sales Market Share by Country in 2023
Figure 57. Europe Bevacizumab Generics Revenue Market Share by Country (2019-2024)
Figure 58. Europe Bevacizumab Generics Sales Market Share byType (2019-2024)
Figure 59. Europe Bevacizumab Generics Sales Market Share by Application (2019-2024)
Figure 60. Germany Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 61.France Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 62. UK Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 63. Italy Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 64. Russia Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 65. Middle East & Africa Bevacizumab Generics Sales Market Share by Country (2019-2024)
Figure 66. Middle East & Africa Bevacizumab Generics Sales Market Share byType (2019-2024)
Figure 67. Middle East & Africa Bevacizumab Generics Sales Market Share by Application (2019-2024)
Figure 68. Egypt Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 69. South Africa Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 70. Israel Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 71.Turkey Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 72. GCC Countries Bevacizumab Generics Revenue Growth 2019-2024 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Bevacizumab Generics in 2023
Figure 74. Manufacturing Process Analysis of Bevacizumab Generics
Figure 75. Industry Chain Structure of Bevacizumab Generics
Figure 76. Channels of Distribution
Figure 77. Global Bevacizumab Generics Sales MarketForecast by Region (2025-2030)
Figure 78. Global Bevacizumab Generics Revenue Market ShareForecast by Region (2025-2030)
Figure 79. Global Bevacizumab Generics Sales Market ShareForecast byType (2025-2030)
Figure 80. Global Bevacizumab Generics Revenue Market ShareForecast byType (2025-2030)
Figure 81. Global Bevacizumab Generics Sales Market ShareForecast by Application (2025-2030)
Figure 82. Global Bevacizumab Generics Revenue Market ShareForecast by Application (2025-2030)
